Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-04-10
1992-11-10
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514397, 514398, 514399, 514400, 514401, 514825, 514838, 514851, 514885, 514893, 514921, 514924, A61K 31415
Patent
active
051623617
ABSTRACT:
The present invention relates to a method of treating diseases associated with elevated levels of interleukin 1 (IL-1) including inflammatory diseases such as arthritis, skin hypersensitivity and endotoxemia. More specifically, the invention relates to a method for the treatment of such diseases in warm-blooded animals, such as humans, which comprises the administration of a therapeutically effective amount of an aromatic diamidine, sufficient to inhibit IL-1 release from IL-1 producing cells. The aromatic diamidine can also be used to block interleukin 6 (IL-6) and tumor necrosis factor from cells producing these cytokines.
REFERENCES:
patent: 4073922 (1978-02-01), Wyburn-Mason
patent: 4119723 (1978-10-01), Wyburn-Mason
patent: 4183941 (1980-01-01), Wyburn-Mason
patent: 4218449 (1980-08-01), Wyburn-Mason
patent: 4376124 (1983-03-01), Carlson et al.
patent: 4399151 (1983-08-01), Sjoerdsma et al.
patent: 4426384 (1984-01-01), Wyburn-Mason
patent: 4757049 (1988-07-01), Plotnikoff
patent: 4804651 (1989-02-01), Duvic et al.
patent: 4895719 (1990-01-01), Radhakrishnan et al.
patent: 4906476 (1990-03-01), Radhakrishnan
patent: 4920016 (1990-04-01), Allen et al.
patent: 4933347 (1990-06-01), Tidwell et al.
patent: 4956355 (1990-09-01), Prendergast
patent: 4971802 (1990-11-01), Tarcsay et al.
patent: 4983397 (1991-01-01), Schroit et al.
patent: 5006343 (1991-04-01), Benson et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5026687 (1991-06-01), Yarchoan et al.
Ferrante et al. C.A. 103: 327g (1985).
Maloff et al., C.A. 111: 224962p (1989); C.A. 111: 192836g (1989).
Allison et al., C.A. 109: 228038y (1988); Connolly et al., C.A. 109: 67102x (1988).
De Young et al., C.A. 107: 168454c (1987); Abul et al., C.A. 106: 169298w (1987).
Domer et al., C.A. 108: 202733a (1988); Nair et al., C.A. 101: 17677c (1984); Dreher et al., C.A. 101: 103773n (1984).
Logan et al., C.A. 107: 198753s (1987); Buxade, C.A. 108: 132166s (1988); Scudeletti et al., C.A. 113: 52657r (1990).
Kusnecov et al., C.A. 112: 229863n (1990); Roth et al., C.A. 110: 133402u (1989); Ruso et al., C.A. 98: 209711a (1983).
Tarayre et al., C.A. 93: 639k (1980).
Rosenthal, G. J. et al., "Inhibition of Cytokine Secretion by Diamidine Compounds", FASEB J., vol. 4, Issue 7, Apr. 26, 1990, p. A1858, Abstracts of Joint Meeting, American Society of Biochemistry and Molecular Biology and American Association of Immunologists, New Orleans, Jun. 4-7, 1990--Oral Presentation, no full written article ever existed.
Rosenthal, G. J. et al., "Pentamidine: An Inhibitor of Interleukin-1 that Acts via a Post-Translational Event", Toxicology and Applied Pharmacology, vol. 107, issue 3, 1991, pp. 55-61.
Therapie 22(4) (Fr) 1967.
Debs et al., Successful Treatment with Aerosolized Pentamidine of Pneumocystis carinii Pneumonia in Rats, Antimicrobial Agents and Chemotherapy, vol. 31, No. 1, pp. 37-41, Jan. 1987.
Special Report, Aerosolized Pentamidine, The Latest on the Current Controversy, AIDS Patient Care, Apr. 1989.
Kasahara et al., The Role of Monokines in Granuloma Formation in Mice: The Ability of Interleukin 1 and Tumor Necrosis Factor-.alpha. to Induce Lung Granulomas, Clinical Immunology and Immunopathology 51, 419-425 (1989).
Girard et al., Pentamidine Aerosol in Prophylaxis and Treatment of Murine Pneumocystis carinii Pneumonia, Antimicrobial Agents and Chemotherapy, vol. 31, No. 7, pp. 978-981, Jul. 1987.
Shen et al., Pentamidine-Induced Pancreatic Beta-Cell Dysfunction, The American Journal of Medicine, vol. 86, pp. 726-728, Jun. 1989.
Ahmed et al., Effect of Anticancer Drugs on Cytokine Release, Int. J. Immunotherapy IV(3) 137-143 (1988).
Blaylock Benny
Comment Christine
Corsini Emanuela
Craig William
Kouchi Yasuhida
Rose Shep K.
The United States of America as represented by the Secretary, De
LandOfFree
Method of treating diseases associated with elevated levels of i does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating diseases associated with elevated levels of i, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating diseases associated with elevated levels of i will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2293210